A compound of Formula a tautomer or a stereoisomeric form thereof, wherein R 1 is -Ar 1, -O-Ar 1 or -NH-Ar 1; Ar 1 is phenyl, pyridinyl, indazolyl, pyrazolyl, indolyl, imidazolyl, benzimidazolyl, thienyl, quinazolinyl, benzo[ b]thienyl, benzofuranyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2- a]pyridinyl, 1,3-dihydro-1-oxo-2H-isoindolyl, 1,3-dihydro-1,3-dioxo-2H-isoindolyl, naphthyl, isoquinolinyl, quinolinyl, cinnolinyl, furanyl or 2,3-dihydro-2-oxo-1H-benzimidazolyl; each optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkylcarbonyl, C 1-4 alkyloxy, halo, Ar 2 and C 1-4 alkyl substituted with one or more halo atoms; Ar 2 is phenyl, thienyl, furanyl, isoxazolyl, oxazolyl or pyrazolyl; each optionally substituted with 1, 2 or 3 C 1-4 alkyl groups; R 2 and R 3 are the same and are hydrogen or fluoro; A is CH or N; R 4 is hydrogen, chloro or fluoro; R 5 is hydrogen, -OR 7 or -O-(CH 2) m -O-R 7; R 6 is hydrogen, -OR 8 or -O-(CH 2) m -O-R 8; provided that at least one of R 5 and R 6 is not hydrogen; or R 5 and R 6 are taken together to form the bivalent radical -O-(CH 2)n-O-; n is 1, 2 or 3; m is 1, 2, 3 or 4; R 7 is C 1-4 alkyl optionally substituted with one NR 9a R 10a; R 8 is C 1-4 alkyl optionally substituted with one NR 9b R 10b; R 9a and R 10a each independently are hydrogen or C 1-4 alkyl; or R 9a and R 10a are taken together with the nitrogen to which they are attached to form a saturated monocyclic 4, 5, 6 or 7-membered heterocycle which may further contain one additional heteroatom selected from O, S, S(=O) p or N; and which heterocycle may optionally be substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo and C 1-4 alkyl; R 9b and R 10b each independently are hydrogen or C 1-4 alkyl; or R 9b and R 10b are taken together with the nitrogen to which they are attached to form a saturated monocyclic 4, 5, 6 or 7-membered heterocycle which may further contain one additional heteroatom selected from O, S, S(=O) p or N; and which heterocycle may optionally be substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo and C 1-4 alkyl; p is 1 or 2; or a pharmaceutically acceptable addition salt or a solvate thereof. R 1 is -Ar 1, -O-Ar 1 or -NH-Ar 1; Ar 1 is phenyl, pyridinyl, indazolyl, pyrazolyl, indolyl, imidazolyl, benzimidazolyl, thienyl, quinazolinyl, benzo[ b]thienyl, benzofuranyl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[1,2- a]pyridinyl, 1,3-dihydro-1-oxo-2H-isoindolyl, 1,3-dihydro-1,3-dioxo-2H-isoindolyl, naphthyl, isoquinolinyl, quinolinyl, cinnolinyl, furanyl or 2,3-dihydro-2-oxo-1H-benzimidazolyl; each optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkylcarbonyl, C 1-4 alkyloxy, halo, Ar 2 and C 1-4 alkyl substituted with one or more halo atoms; Ar 2 is phenyl, thienyl, furanyl, isoxazolyl, oxazolyl or pyrazolyl; each optionally substituted with 1, 2 or 3 C 1-4 alkyl groups; R 2 and R 3 are the same and are hydrogen or fluoro; A is CH or N; R 4 is hydrogen, chloro or fluoro; R 5 is hydrogen, -OR 7 or -O-(CH 2) m -O-R 7; R 6 is hydrogen, -OR 8 or -O-(CH 2) m -O-R 8; or R 5 and R 6 are taken together to form the bivalent radical -O-(CH 2)n-O-; n is 1, 2 or 3; m is 1, 2, 3 or 4; R 7 is C 1-4 alkyl optionally substituted with one NR 9a R 10a; R 8 is C 1-4 alkyl optionally substituted with one NR 9b R 10b; R 9a and R 10a each independently are hydrogen or C 1-4 alkyl; or R 9a and R 10a are taken together with the nitrogen to which they are attached to form a saturated monocyclic 4, 5, 6 or 7-membered heterocycle which may further contain one additional heteroatom selected from O, S, S(=O) p or N; and which heterocycle may optionally be substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo and C 1-4 alkyl; R 9b and R 10b each independently are hydrogen or C 1-4 alkyl; or R 9b and R 10b are taken together with the nitrogen to which they are attached to form a saturated monocyclic 4, 5, 6 or 7-membered heterocycle which may further contain one additional heteroatom selected from O, S, S(=O) p or N; and which heterocycle may optionally be substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo and C 1-4 alkyl; p is 1 or 2;